The recent developments about
Thermo Fisher Scientific (TMO) reveal that a number of financial institutions are upgrading their perspectives of the company and subsequently increasing their price targets. Prominently,
Citigroup and
Morgan Stanley analysts have upgraded the stock to 'Buy' with raised target prices. Meanwhile,
Goldman Sachs has also initiated coverage of the stock with a buy rating. There have been ongoing changes in the ownership of the company's shares, with both purchases and sell-offs reported by several investment groups. Additionally, the stock's recent price pullback and unusual options activity have merited attention. Key financial indicators show a 10% monthly share price surge and substantial revenue growth in the Q3 2025 earnings call. It's also noted that
TMO beats Q3 earnings and revenues estimates. In an interesting development, Thermo Fisher's new Asia Bioprocessing Network might reshape the narrative for investing in the company. Recently, Thermo Fisher announced
$5 Billion of share repurchases and a quarterly dividend.
Citigroup upgraded TMO from neutral to buy, adjusting the price target to $660 from $580. Furthermore, Thermo Fisher has partnered with
OpenAI which could potentially boost drug development innovation.
Thermo Fisher Scientific TMO News Analytics from Thu, 08 May 2025 07:00:00 GMT to Sat, 13 Dec 2025 10:53:09 GMT -
Rating 8
- Innovation 7
- Rumor 3
